The BD ProbeTec HSV-1 and HSV-2 Qx Amplified DNA assays will run on the BD Viper System with XTR Technology, which uses Strand Displacement Amplification technology to qualitatively detect and differentiate HSV-1 and HSV-2 DNA in clinician-collected external anogenital lesion specimens.
The new BD ProbeTec HSV-1 and HSV-2 Qx assays will improve accuracy and time to results over culture methods, which often take 2-10 days for results.
BD‘s new automated HSV assays will provide laboratories with the capability to read up to 96 positive or negative results in about two and a half hours.
Using the BD Viper System with XTR Technology, laboratories also will be able to run tests for chlamydia and gonorrhea, along with HSV-1 and HSV-2, on a single automated run.
BD Diagnostics Women’s Health and Cancer vice president and general manager Wayne Brinster said that when caring for a patient who may be suffering from HSV, clinicians need a precise picture of what they are dealing with.
"Determining whether a patient has HSV and whether it is type 1 or 2 makes a big difference in how the infection is treated, especially with the increase in new anti-viral and suppressive therapies," Brinster said.
